Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease
Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease
复制标题
DOI：
10.1182/blood.v95.1.83.001k18_83_89
复制
发表时间：
2000-01-01
期刊：
影响因子：
20.3
通讯作者：
Light, S
中科院分区：
文献类型：
--
作者：
Przepiorka, D;Kernan, NA;Light, S
Daclizumab是一种针对白细胞介素2受体（IL-2 R）α链的人源化单克隆抗体，是IL-2对活化淋巴细胞的竞争性抑制剂。为了验证特异性抑制活化淋巴细胞可能改善急性移植物抗宿主病（GVHD）的假说，我们用Daclizumab治疗了43例晚期或激素难治性GVHD患者。第一组24例患者在第1、8、15、22和29天接受达克珠单抗1 mg/kg治疗，第43天完全缓解（CR）率为29%（95%置信区间[CI]，13%-51%），第120天生存率为29%（95% CI，13%-51%），第二组19例患者在第1、4、8、15和22天接受达克珠单抗1 mg/kg治疗，对于这些患者，第43天的CR率为47%治疗后，可溶性IL-2 R和外周血CD 3（+）25（+）淋巴细胞的血清浓度降低，但这些变化不能预测应答。达克珠单抗具有治疗急性GVHD的显著活性，推荐评价的第二种方案用于对照研究。(C)2000年，美国血液学会。
Daclizumab, a humanized monoclonal IgG1 directed against the a chain of the interleukin-2 receptor (IL-2R), is a competitive inhibitor of IL-2 on activated lymphocytes, To test the hypothesis that specific inhibition of activated lymphocytes in patients with ongoing acute graft-versus-host disease (GVHD) might ameliorate the process, we treated 43 patients with advanced or steroid-refractory GVHD with daclizumab. The first cohort of 24 patients was treated with daclizumab 1 mg/kg on days 1, 8, 15, 22, and 29, On day 43, the complete response (CR) rate was 29% (95% confidence interval [CI], 13%-51%), Survival on day 120 was 29% (95% CI, 13%-51%), A second cohort of 19 patients was treated with daclizumab 1 mg/kg on days 1, 4, 8, 15, and 22, For these patients, the CR rate on day 43 was 47% (95% CI, 24%-71%), and survival on day 120 was 53% (95% CI, 29%-76%), There were no infusion-related reactions and no serious side effects related to daclizumab, Following treatment, there was a reduction in serum concentrations of soluble IL-2R and peripheral blood CD3(+)25(+) lymphocytes, but these changes were not predictive of response. Daclizumab has substantial activity for the treatment of acute GVHD, and the second regimen evaluated is recommended for a controlled study. (C) 2000 by The American Society of Hematology.